interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Epinephrine

Generic competition · all medicines · read 12 November 2026

Is there a generic of Epinephrine, and who makes it?

Epinephrine appears in 9 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 10 generic makers listed as marketed across them. 4 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 5.6 and 30.7 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Epinephrine9 dosage-form groups in the Orange Book
10generic makers listed
  1. Epinephrine appears in 9 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 10 generic makers listed as marketed across them.
  2. 4 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 5.6 and 30.7 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Intramuscular, Intravenous, Subcutaneous

Four or more generic makers listed

Brand listed as marketed: Adrenalin and Epinephrine. 8 generic makers with 11 generic products listed as marketed; the first generic approval is dated 6 July 2018.

2010201520202025203020352040204508brand 2012International Medication Systems Ltd, first approval 24 April 2020American Regent Inc, first approval 6 September 2024Gland Pharma Ltd, first approval 6 February 2025Amneal Eu Ltd, first approval 14 October 2025Hikma Pharmaceuticals Usa Inc, first approval 29 May 2026Deva Holding Anonim Sirketi, first approval 31 July 2026Zydus Pharmaceuticals Usa Inc, first approval 14 September 2026Apotex Inc, first approval 15 September 2026data datePatent 9295657 listed to expire 13 March 2035Patent 9119876 listed to expire 13 March 2035Patent 12280024 listed to expire 13 March 2035Patent 10130592 listed to expire 13 March 2035Patent 12539283 listed to expire 17 January 2045
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
International Medication Systems Ltd24 April 20201
American Regent Inc6 September 20241
Gland Pharma Ltd6 February 20253
Amneal Eu Ltd14 October 20252
Hikma Pharmaceuticals Usa Inc29 May 20261
Deva Holding Anonim Sirketi31 July 20261
Zydus Pharmaceuticals Usa Inc14 September 20261
Apotex Inc15 September 20261

Patents and exclusivities still listed

  • 13 March 2035Patent 9295657
  • 13 March 2035Patent 9119876 drug product
  • 13 March 2035Patent 12280024 drug product
  • 13 March 2035Patent 10130592 drug product
  • 17 January 2045Patent 12539283 drug product

Injectable, Intramuscular, Subcutaneous

One to three generic makers listed

Brand listed as marketed: Adrenaclick, Epipen and Epipen Jr.. 1 generic maker with 2 generic products listed as marketed; the first generic approval is dated 16 August 2018.

198519901995200020052010201520202025203001brand 1987Teva Pharmaceuticals Usa Inc, first approval 16 August 2018data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Teva Pharmaceuticals Usa Inc16 August 20182

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Adrenalin and Epinephrine. No generic is listed as marketed.

20152020202520302035204001brand 2019data datePatent 11083698 listed to expire 21 March 2039Patent 10653646 listed to expire 21 March 2039Patent 11207280 listed to expire 21 March 2039Patent 12133837 listed to expire 21 March 2039
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 21 March 2039Patent 11083698
  • 21 March 2039Patent 10653646 drug product
  • 21 March 2039Patent 11207280 drug product
  • 21 March 2039Patent 12133837 drug product

Solution, Intramuscular, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Auvi-Q and Symjepi. No generic is listed as marketed.

201020152020202520302035204001brand 2012data datePatent 11590286 listed to expire 12 December 2026Patent 8206360 listed to expire 27 February 2027Patent 7947017 listed to expire 12 March 2028Patent 8231573 listed to expire 25 November 2028Patent 8226610 listed to expire 10 April 2029Patent 8021344 listed to expire 2 November 2029Patent 11141540 listed to expire 20 October 2036Patent 10688244 listed to expire 21 December 2037Patent 10842938 listed to expire 21 December 2037Patent 11771830 listed to expire 21 December 2037
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 12 December 2026Patent 11590286 drug product
  • 27 February 2027Patent 8206360 drug product
  • 12 March 2028Patent 7947017 drug product
  • 25 November 2028Patent 8231573 drug product
  • 10 April 2029Patent 8226610 drug product
  • 2 November 2029Patent 8021344 drug product
  • 20 October 2036Patent 11141540 drug product
  • 21 December 2037Patent 10688244 drug product

2 more patents are listed.

Aerosol, Metered, Inhalation

Brand listed, no generic listed as marketed

Brand listed as marketed: Primatene Mist. No generic is listed as marketed (1 generic product listed as discontinued).

201520202025203001brand 2018data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous, Intraocular, Intramuscular, Subcutaneous

One to three generic makers listed

Brand listed as marketed: Epinephrine. 2 generic makers with 2 generic products listed as marketed; the first generic approval is dated 20 November 2024.

2010201520202025203002brand 2014Fresenius Kabi Usa Llc, first approval 20 November 2024Gland Pharma Ltd, first approval 3 June 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Fresenius Kabi Usa Llc20 November 20241
Gland Pharma Ltd3 June 20251

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Injectable, Injection

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

1995200020052010201520202025203001brand 1999data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Injectable, Intramuscular

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

1995200020052010201520202025203001brand 1995data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Spray, Nasal

Brand listed, no generic listed as marketed

Brand listed as marketed: Neffy. No generic is listed as marketed.

2020202520302035204001brand 2024data datePatent 11173209 listed to expire 6 February 2038Patent 10576156 listed to expire 6 February 2038Patent 11918655 listed to expire 6 February 2039Patent 11744895 listed to expire 6 February 2039Patent 11717571 listed to expire 6 February 2039Patent 11191838 listed to expire 6 February 2039Patent 10682414 listed to expire 6 February 2039Patent 12324838 listed to expire 6 February 2039
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 6 February 2038Patent 11173209
  • 6 February 2038Patent 10576156 drug product
  • 6 February 2039Patent 11918655
  • 6 February 2039Patent 11744895
  • 6 February 2039Patent 11717571
  • 6 February 2039Patent 11191838 drug product
  • 6 February 2039Patent 10682414
  • 6 February 2039Patent 12324838 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.